Entities / Company
Silence Therapeutics.
UK business
- Reports this week
- 1
- Active events
- 1
- Connections
- 20
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
One to three months ago
-
FDA turned back ITM's experimental treatment, while Silence Therapeutics' divesiran was identified as a potential competitive threat to rusfertide.Some support1 report
-
Silence Therapeutics received designations for its divesiran program from the FDA, leading to stock price movement.Some support1 report
-
Silence Therapeutics is listed on the Nasdaq stock exchange.Some support1 report
-
Silence Therapeutics was required to file disclosures with the Securities and Exchange Commission on July 31, 2026.Some support1 report
Gone quiet
No new reports in 90+ days-
Richard Griffiths holds the largest shareholder stake in Silence Therapeutics, according to reports from July 2025.Speculative1 report
-
Silence Therapeutics reported its financial results from London on August 7, 2025.Some support1 report
-
Morgan Stanley, Silence Therapeutics, and H.C. Wainwright are involved in a conference on September 2, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Silence Therapeutics this week
News at the entities that move Silence Therapeutics most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Silence Therapeutics
-
Securities and Exchange Commission StructuralBlackRock, the manager of the iShares Core MSCI EAFE ETF, has made required filings with the Securities and Exchange Commission regarding institutional holdings.Moves Silence Therapeutics
-
Morgan Stanley OperationalFinancial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Moves Silence Therapeutics
-
Cantor Fitzgerald Mentioned togetherAnalyst firm lowered price targets on Automatic Data Processing (ADP) stock on June 6, 2026.Moves Silence Therapeutics
-
Nasdaq StructuralApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Silence Therapeutics
Connections
The 5 strongest of 20, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
Silence Therapeutics is seeking regulatory designations and approval from the FDA for its divesiran program.
-
Securities and Exchange Commission Structural
Silence Therapeutics is required to file disclosures with the Securities and Exchange Commission.
-
Morgan Stanley Operational
Morgan Stanley actively analyzes and upgrades the rating of Silence Therapeutics, influencing its market valuation.
-
Nasdaq Structural
The company is listed on the Nasdaq stock exchange, relying on its market infrastructure for public trading.
-
Cantor Fitzgerald Mentioned together
Cantor Fitzgerald has initiated market coverage and issued ratings for Silence Therapeutics.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
3 events- FDA turned back ITM's experimental treatment, while Silence Therapeutics' divesiran was identified as a potential competitive threat to rusfertide.
- Silence Therapeutics received designations for its divesiran program from the FDA, leading to stock price movement.
- Silence Therapeutics is listed on the Nasdaq stock exchange.
July 2026
1 eventShow 1 earlier month
June 2026
3 events- Richard Griffiths holds the largest shareholder stake in Silence Therapeutics, according to reports from July 2025.
- Silence Therapeutics reported its financial results from London on August 7, 2025.
- Morgan Stanley, Silence Therapeutics, and H.C. Wainwright are involved in a conference on September 2, 2025.